Cancer researchers hit a bullseye with new drug target for Ewing sarcoma

(Boston Children's Hospital) Kimberly Stegmaier of Dana-Farber/Boston Children's Cancer and Blood Disorders Center and collaborators have found that Ewing sarcoma cells die if an enzyme called CDK12 is knocked out genetically or chemically inhibited. What's more, when a CDK12 inhibitor is combined with another drug, called a PARP inhibitor, the two drugs double down to deliver a lethal punch to Ewing sarcoma cells.
Source: EurekAlert! - Biology - Category: Biology Source Type: news